← Back to Clinical Trials
Recruiting NCT05933707

NCT05933707 Small Extracellular Vesicles and Insulin Action

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05933707
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Obesity
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2023-06-08
Primary Completion 2029-01-01

Trial Parameters

Condition Obesity
Sponsor Washington University School of Medicine
Study Type INTERVENTIONAL
Phase N/A
Enrollment 72
Sex ALL
Min Age 25 Years
Max Age 55 Years
Start Date 2023-06-08
Completion 2029-01-01
Interventions
People with Metabolically Unhealthy Obesity - Low Calorie Diet

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.

Eligibility Criteria

Inclusion Criteria: * Metabolically healthy lean subjects must have a BMI ≥18.5 and ≤24.9 kg/m²; Subjects with obesity must have a BMI ≥30.0 and ≤50.0 kg/m² * Metabolically healthy lean and people with metabolically healthy obesity must have intrahepatic triglyceride (IHTG) content ≤5%; fasting plasma glucose concentration \<100 mg/dl, 2-hr oral glucose tolerance plasma glucose concentration \<140 mg/dl, hemoglobin A 1C (HbA1c) ≤5.6% and HOMA-IR \<2.5. * People with metabolically unhealthy obesity must have intrahepatic triglyceride (IHTG) content ≥5.6%; HOMA-IR ≥2.5, and HbA1c 5.7%-6.4%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg/dl. Exclusion Criteria: * History of diabetes, liver disease other than NAFLD or other serious diseases, * Consume excessive amounts of alcohol (\>21 units/week for men and \>14 units/week for women), * Take medications that could affect the study outcome measures, engage

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology